Kiadis Pharma Awarded a €3 mil­lion Innovation Credit from the Dutch Government for Phase II Clinical Development Program

Amsterdam, The Netherlands, June 26, 2013 – Kiadis Pharma B.V., a clin­i­cal stage bio­phar­ma­ceu­ti­cal com­pa­ny devel­op­ing treat­ments for blood can­cers, announced today that it will receive an inno­va­tion cred­it of up to €3 mil­lion from AgentschapNL, a divi­sion of the Dutch Ministry of Economic Affairs, to sup­port the Phase II clin­i­cal devel­op­ment of Kiadis Pharma’s lead pipeline prod­uct, ATIR™.
Kiadis Pharma is cur­rent­ly con­duct­ing a Phase II inter­na­tion­al mul­ti-cen­ter study with ATIR™, its cell based prod­uct for blood can­cers, in order to con­firm and extend pre­vi­ous Phase I/II results.
Manfred Ruediger, PhD, Chief Executive Officer of Kiadis Pharma, com­ment­ed: “We are delight­ed to receive this cred­it for ATIR™ as these awards are only made to inno­v­a­tive projects with strong com­mer­cial prospects. The grant allows us to accel­er­ate our clin­i­cal devel­op­ment in this impor­tant ther­a­peu­tic area of blood can­cer treat­ment which has high med­ical impor­tance for patients.”

About ATIR™
ATIR™ is a cell based med­i­c­i­nal prod­uct enabling stem cell trans­plan­ta­tions using par­tial­ly mis­matched (hap­loiden­ti­cal) fam­i­ly mem­bers as donors for patients suf­fer­ing from blood can­cer who lack a suit­able stan­dard of care matched donor. Stem cell trans­plan­ta­tion is the only poten­tial­ly cura­tive treat­ment for many patients but a match­ing donor is avail­able for only half of the patients in need. ATIR™ thus has the poten­tial to address this unmet need and to make stem cell trans­plan­ta­tions avail­able for all patients world­wide.
Those T-cells in a hap­loiden­ti­cal graft which would cause Graft-ver­sus-Host-Disease (GvHD) are selec­tive­ly elim­i­nat­ed using pro­pri­etary tech­nol­o­gy to pro­duce ATIR™. ATIR™ is admin­is­tered as an adjunc­tive treat­ment after a hap­loiden­ti­cal stem cell trans­plan­ta­tion facil­i­tat­ing ear­ly immune recon­sti­tu­tion with­out caus­ing life-threat­en­ing (acute) GvHD.
In a Phase I/II study with ATIR™, safe­ty and proof of con­cept were con­firmed in terms of absence of grade III/IV GvHD, reduced rates of infec­tion, reduced Transplant Related Mortality and high Overall Survival.
ATIR™ is cur­rent­ly in Phase II clin­i­cal devel­op­ment and has been grant­ed Orphan Drug Designation both in the EU and the USA. In these regions, 20,000 to 25,000 patients a year are unable to find a suit­able stan­dard of care matched donor. Together, both regions rep­re­sent a com­bined pri­ma­ry mar­ket poten­tial of more than EUR 1 bil­lion per year.

Leave a Reply

Your email address will not be published. Required fields are marked *